Identification of Major Histocompatibility Complex Class II Epitopes From Lyme Autoantigen Apolipoprotein B-100 and Borrelia burgdorferi Mcp4 in Murine Lyme Arthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Jan. 2011- : Oxford : Oxford University Press
      Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press
    • Subject Terms:
    • Abstract:
      Background: During infection with the Lyme arthritis (LA) pathogen Borrelia burgdorferi, T-cell responses to both host and pathogen are dysregulated, resulting in chronic infection and frequent development of autoimmunity.
      Methods: To assess CD4+ T-cell epitopes presented during development of LA, we used an unbiased, immunopeptidomics approach to characterize the major histocompatibility complex (MHC) class II immunopeptidome in B burgdorferi-infected C57BL/6 (B6) mice, which develop mild, self-limiting LA, and infected B6 Il10-/- mice, which develop severe, persistent LA at 0, 4, and 16 weeks postinfection (22-23 mice per group).
      Results: Peptides derived from proteins involved in adaptive T- and B-cell responses and cholesterol metabolism, including human Lyme autoantigen apolipoprotein B-100 (apoB-100), were enriched in infected Il10-/- mice; whereas peptides derived from proteins involved in neutrophil extracellular net formation were enriched in infected B6 mice. Presentation of apoB-100 peptides showed evidence of epitope expansion during infection. Of several identified B burgdorferi peptides, only 1, a methyl-accepting chemotaxis protein peptide Mcp4442-462, was immunogenic.
      Conclusions: ApoB-100, a human Lyme autoantigen, undergoes marked epitope expansion during LA development. The paucity of immunogenic B burgdorferi epitopes supports previous findings suggesting CD4+ T-cell responses are suppressed in murine LA.
      (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].)
    • References:
      J Infect Dis. 1990 Jul;162(1):133-8. (PMID: 2141344)
      J Immunol. 2023 Sep 15;211(6):994-1005. (PMID: 37556156)
      Nat Rev Microbiol. 2012 Jan 09;10(2):87-99. (PMID: 22230951)
      Circulation. 2020 Sep 29;142(13):1279-1293. (PMID: 32703007)
      Nat Rev Rheumatol. 2021 Aug;17(8):449-461. (PMID: 34226730)
      J Immunol. 2012 Feb 1;188(3):1381-93. (PMID: 22180617)
      BMJ Glob Health. 2022 Jun;7(6):. (PMID: 35697507)
      Front Immunol. 2017 Feb 20;8:116. (PMID: 28265270)
      J Autoimmun. 2009 Nov-Dec;33(3-4):197-207. (PMID: 19819109)
      J Clin Invest. 2023 Sep 1;133(17):. (PMID: 37471146)
      PLoS One. 2015 Aug 07;10(8):e0135142. (PMID: 26252010)
      Clin Infect Dis. 2023 Sep 18;77(6):839-847. (PMID: 37227948)
      Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5491-6. (PMID: 25870274)
      Nat Rev Cardiol. 2022 Mar;19(3):168-179. (PMID: 34625741)
      N Engl J Med. 2002 Sep 19;347(12):911-20. (PMID: 12239261)
      Nat Rev Dis Primers. 2016 Dec 15;2:16090. (PMID: 27976670)
      Int J Mol Sci. 2022 Sep 29;23(19):. (PMID: 36232786)
      Infect Dis Clin North Am. 2022 Sep;36(3):621-638. (PMID: 36116839)
      Curr Opin Immunol. 2022 Aug;77:102187. (PMID: 35550259)
      Ticks Tick Borne Dis. 2021 Mar;12(2):101611. (PMID: 33360386)
      Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1961-7. (PMID: 10938018)
      J Proteome Res. 2015 Jun 5;14(6):2686-95. (PMID: 25894274)
      J Immunol. 2012 Sep 1;189(5):2488-501. (PMID: 22851707)
      Emerg Infect Dis. 2021 Feb;27(2):616-619. (PMID: 33496229)
      Clin Lab Med. 2015 Dec;35(4):765-78. (PMID: 26593256)
      Infect Dis Clin North Am. 2015 Jun;29(2):309-23. (PMID: 25999226)
      Infect Dis Clin North Am. 2022 Sep;36(3):563-577. (PMID: 36116835)
      EBioMedicine. 2023 Apr;90:104524. (PMID: 36958992)
      Immunol Rev. 2020 Mar;294(1):63-79. (PMID: 31930745)
      PLoS Pathog. 2022 Oct 20;18(10):e1010903. (PMID: 36265003)
      Front Immunol. 2013 Dec 27;4:493. (PMID: 24416033)
      Infect Dis Clin North Am. 2015 Jun;29(2):187-210. (PMID: 25999219)
      Autoimmunity. 2007 Mar;40(2):122-30. (PMID: 17453711)
      J Proteome Res. 2020 Feb 7;19(2):610-623. (PMID: 31821002)
      J Immunol. 2018 Feb 15;200(4):1457-1470. (PMID: 29330323)
      Nat Rev Microbiol. 2003 Nov;1(2):151-7. (PMID: 15035044)
      J Proteome Res. 2017 Jan 6;16(1):122-136. (PMID: 27726376)
      PLoS One. 2014 Jul 22;9(7):e102236. (PMID: 25050824)
      Clin Immunol. 2015 Oct;160(2):336-41. (PMID: 26187145)
      Arthritis Rheum. 2013 Jan;65(1):186-96. (PMID: 23044924)
      J Infect Dis. 2015 Dec 1;212(11):1841-50. (PMID: 26014802)
      Front Med (Lausanne). 2021 Aug 18;8:666554. (PMID: 34485323)
      J Autoimmun. 2016 May;69:24-37. (PMID: 26922382)
      PLoS Pathog. 2015 Jul 02;11(7):e1004976. (PMID: 26136236)
      Hepatology. 1996 Jun;23(6):1412-7. (PMID: 8675158)
      Mol Cell Proteomics. 2011 Mar;10(3):M110.002477. (PMID: 21081667)
      PLoS Biol. 2020 Jul 14;18(7):e3000411. (PMID: 32663221)
      J Clin Invest. 2020 May 1;130(5):2148-2151. (PMID: 32281948)
      Front Immunol. 2017 Feb 23;8:95. (PMID: 28280493)
      Infect Immun. 2015 Jan;83(1):48-56. (PMID: 25312948)
    • Grant Information:
      R21 AI148982 United States AI NIAID NIH HHS; W81XWH-22-1-0728 US Department of Defense; National Institute of Allergy and Infectious Diseases; 1R21AI148982 United States NH NIH HHS
    • Contributed Indexing:
      Keywords: Lyme arthritis; T-cell; apolipoprotein B-100; autoimmunity; immunopeptidome
    • Accession Number:
      0 (Apolipoprotein B-100)
      0 (Autoantigens)
      0 (Epitopes, T-Lymphocyte)
      0 (Histocompatibility Antigens Class II)
      130068-27-8 (Interleukin-10)
      0 (APOB protein, human)
    • Publication Date:
      Date Created: 20240814 Date Completed: 20240814 Latest Revision: 20240920
    • Publication Date:
      20240920
    • Accession Number:
      PMC11322890
    • Accession Number:
      10.1093/infdis/jiae324
    • Accession Number:
      39140726